Incyte Corporation INCY

123.36 (1.46) (1.17%) as of 29 Sep
Market cap
$26.1B
P/E
15.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Incyte Corporation (INCY) Operating margin

Incyte Corporation's operating margin over the twelve months to 30 June 2026 was 30.6%, up 1.1 percentage points from fiscal 2025 (29.5%). Over the past ten years it has ranged from −15.8% (fiscal 2017) to 29.5% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.

Operating margin, annual

Annual

Period Operating margin Change (points)
FY2025 29.5% 28.01
FY2024 1.45% (15.34)
FY2023 16.8% (0.28)
FY2022 17.1% (2.55)
FY2021 19.6% 29.51
FY2020 −9.89% (28.51)
FY2019 18.6% 11.75
FY2018 6.87% 22.71
FY2017 −15.8% (28.95)
FY2016 13.1% 6.39

Quarterly

Period Operating margin Change (points)
Jun 2026 41.7% 18.03
Mar 2026 23.7% 1.37
Dec 2025 22.3% (10.18)
Sep 2025 32.5% (11.16)
42 more quarters

Against its own ten years

Low −15.8% High 29.5%
Ten-year median 13.1%
Current reading's percentile 100

Operating margin against peers

Company Operating margin
RPRX Royalty Pharma PLC compare 59.6%
INCY Incyte Corporation 30.6%
GMAB Genmab A/S Sponsored ADR compare 26.0%
ALNY Alnylam Pharmaceuticals, Inc. compare 20.8%
JAZZ Jazz Pharmaceuticals PLC compare 19.5%
ONC BeOne Medicines Ltd. - Sponsored ADR compare 15.1%
INSM Insmed, Inc. compare −73.9%
BNTX BioNTech SE Sponsored ADR compare −77.9%
ROIV Roivant Sciences Ltd. compare −7,914.8%
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 0.00%

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on INCY